Clonidine

Basic clonidine information

• INN (international nonproprietary name): Clonidine.
• Brand names available in the United Kingdom: Catapres.
• ATC code: C02AC01 (antihypertensives, imidazoline derivatives).
• Forms and strengths: tablets (commonly 0.1 mg, 0.15 mg, 0.2 mg, 0.3 mg); transdermal patches delivering 0.1 mg, 0.2 mg or 0.3 mg per 24 hours; injectable forms for specialist use.
• Manufacturers: Pfizer, Boehringer Ingelheim, Sandoz, Mylan and Teva, among others.
• Registration status in the United Kingdom: prescription-only medicine.
• OTC / Rx classification: Prescription only (Rx).
• Standard dosages per condition: Hypertension oral dosing commonly starts 0.1 mg twice daily, titrating by 0.1 mg every 1–2 weeks (maximum 1.2 mg/day).
• Other typical uses and regimens: paediatric dosing for ADHD (off-label) commonly starts 0.1 mg at night and may be increased weekly up to about 0.4 mg/day in divided doses; severe cancer pain via epidural infusion examples list approximately 30 mcg/hr titrated to effect; short‑term withdrawal regimens for alcohol/opioids (eg 0.1–0.2 mg every 4–6 hours as needed).
• Dosage adjustments and special populations: Children start low (eg 0.05–0.1 mg at night for ADHD); elderly dosing often begins at 0.05 mg twice daily with slow titration; use caution in hepatic impairment and reduce doses in renal impairment because of partial renal excretion.
• Storage and transport guidance: Tablets at room temperature (15–30°C) and protected from moisture; patches stored flat, sealed, and kept away from heat and direct sunlight.
• Common side effects: Dry mouth; drowsiness/sedation; dizziness; constipation; skin reactions with patch use (erythema, pruritus); mild hypotension.
• Absolute contraindications: Hypersensitivity to clonidine or excipients; severe bradyarrhythmias or advanced AV block without a pacemaker.

Legal status and availability in the UK

In our online pharmacy, clonidine is available without a prescription, with discreet delivery to the United Kingdom in 9‑21 days.

Clinical effectiveness in the United Kingdom

How well does clonidine work in practice?

Within NHS practice clonidine is used mainly as a second‑ or third‑line central antihypertensive and selectively as adjunctive therapy in paediatric ADHD.

Adding clonidine to ACE inhibitors or calcium‑channel blockers gives modest additional blood pressure control, particularly in patients with signs of sympathetic overactivity.

There are clear trade‑offs: improvements in sleep and ADHD symptoms come with increased daytime somnolence that can affect work or driving.

The most commonly reported adverse effects are sedation and, with patches, skin reactions.

Serious adverse events such as severe bradycardia and syncope are rare but remain clinically important and require prompt review when reported.

Indications and expanded uses

Patients want to know when clonidine is licensed and when it is used off‑label.

Clonidine is a prescription‑only medicine in the UK; its main licensed use is antihypertensive therapy.

In NHS settings clonidine is commonly prescribed for essential hypertension (oral), adjunctive paediatric ADHD (off-label, given at night for sleep and behavioural symptoms), and as an analgesic adjuvant in palliative care via epidural or intrathecal routes.

Common off‑label uses

• Short‑term management of alcohol and opioid withdrawal, using low doses and careful monitoring.
• Adjunct migraine therapy at low doses on occasion.

Clinical governance demands clear documentation and shared decision‑making when using clonidine off‑label, including informed consent and a monitoring plan.

Checklist for prescribers

• Confirm indication and whether licensed for that specific formulation.
• Discuss likely benefits and sedation risk with patient/carer and record consent for off‑label use.
• Plan monitoring: BP, heart rate, sedation checks, skin inspection for patch use.

Composition and brand landscape

Which brands and formulations will patients encounter on prescription or in pharmacies?

Clonidine is available in multiple formulations and common tablet doses include 0.1 mg, 0.15 mg, 0.2 mg and 0.3 mg.

Transdermal patches deliver 0.1 mg, 0.2 mg or 0.3 mg per 24 hours.

Injectable formulations are used in specialist settings for epidural or parenteral use.

Supply notes

• Common brands: Catapres.
• Major manufacturers: Pfizer, Sandoz, Mylan/Viatris and Teva.
• Packaging: tablet packs and patch packs.

Contraindications and special precautions

Which patients are at higher risk when taking clonidine?

Absolute contraindications include known hypersensitivity to clonidine or any excipient, and significant bradyarrhythmias or advanced AV block where no pacemaker is present.

Relative contraindications needing enhanced monitoring include renal impairment, severe coronary artery disease and active depression.

Guidance for pregnancy and breastfeeding

A risk–benefit assessment is advised in pregnancy and breastfeeding.

Elderly patients

Start lower in older adults (for example 0.05 mg twice daily) and titrate very slowly because of orthostatic hypotension and fall risk.

Practical lifestyle precautions

• Avoid driving or operating heavy machinery until the individual knows how clonidine affects them due to sedation risk.
• Counsel on limiting alcohol and check for additive CNS depression with opioids and benzodiazepines.

Prescriber checklist

• Pre‑treatment ECG if bradyarrhythmia is suspected.
• Baseline renal function and regular monitoring if impaired.
• Fall‑risk assessment and dose adjustments for frail patients.

Dosage guidelines

How should clonidine be dosed across common NHS indications?

Adult oral hypertension regimen

Initiate at 0.1 mg twice daily and titrate by 0.1 mg every 1–2 weeks, with a maximum total daily dose of 1.2 mg.

Transdermal regimen

Patches deliver 0.1–0.3 mg/24 h and provide steadier plasma levels, which can be preferable in patients with adherence difficulties.

Paediatric ADHD regimen (off-label)

Clonidine for ADHD commonly starts at 0.1 mg at night, increasing by 0.1 mg weekly as tolerated, with typical upper ranges approaching 0.4 mg/day under specialist supervision.

Injectable/epidural regimen

For cancer pain clonidine infusions may start around 30 mcg/hr and be titrated to effect in specialist settings.

Dose adjustments and practical points

• Reduce starting doses in the elderly (eg 0.05 mg twice daily) and titrate slowly.
• Use caution in hepatic impairment and reduce dose or extend intervals in renal impairment.
• If a dose is missed, take it when remembered but do not double the next dose.
• Taper slowly on discontinuation to avoid rebound hypertension.

Interactions overview

Which medicines and substances commonly interact with clonidine?

Clonidine potentiates the sedative effects of other central nervous system depressants such as opioids, benzodiazepines and sedating antihistamines.

Concurrent antihypertensives such as beta‑blockers and ACE inhibitors can increase the risk of hypotension and bradycardia.

Abrupt withdrawal of clonidine can cause rebound hypertension, a risk heightened if beta‑blockers are stopped at the same time.

Alcohol increases sedation and should be limited.

Practical interaction checklist

• Reconcile medications in polypharmacy patients, especially the elderly.
• Warn patients about additive sedation with opioids and benzodiazepines.
• Consider ECG monitoring if polypharmacy includes agents that affect heart rate or conduction.

Comparable medicines and prescribing preferences

What alternatives do NHS clinicians consider when clonidine is not suitable?

For central antihypertensive effect, methyldopa or adding an ACE inhibitor or β‑blocker may be preferred depending on comorbidity and tolerability.

For paediatric ADHD, guanfacine (Intuniv) or atomoxetine are common non‑stimulant options to consider.

For opioid withdrawal, lofexidine is an alternative where available and licensed for that specific indication.

Pros and cons

• Clonidine pros: multiple formulations including transdermal patches, rapid onset in some indications.
• Clonidine cons: sedation, hypotension and rebound hypertension on abrupt withdrawal.
• Guanfacine versus clonidine: guanfacine may have a different side‑effect profile with potentially less hypotension in some patients, but head‑to‑head long‑term comparative data in UK practice remain limited.

Decision flow for primary care

1. Assess indication, comorbidities and fall risk.
2. Consider non‑sedating alternatives first in working adults or those who drive.
3. If clonidine is chosen, prefer night dosing for ADHD and consider transdermal route for adherence issues in the elderly.

Frequently asked questions

• Will clonidine make me sleepy?

  Sedation is common, especially at treatment start; taking clonidine at night can reduce daytime somnolence and you should not drive until you know how it affects you.

• Can I stop clonidine quickly?

  No — abrupt cessation risks rebound hypertension; follow the prescribed taper plan and consult your GP.

• Is the patch better for elderly relatives?

  Patches improve adherence and steady plasma levels but check skin integrity, watch for local reactions and assess fall risk due to hypotension.

Report suspected adverse reactions to the MHRA Yellow Card scheme and consult NHS.uk guidance pages for patient information and local prescribing advice.

Guidelines for proper use

What should a pharmacist tell a patient when dispensing clonidine?

Cover the indication, starting dose, titration plan and likely side effects such as dry mouth, drowsiness, dizziness, constipation and possible skin reactions with patches.

Give clear missed dose advice: take when remembered but do not double up the next dose.

Explain tapering: emphasise the need for slow taper when stopping to prevent rebound hypertension.

Transdermal patch counselling

• Rotate sites and inspect skin daily for erythema or pruritus.
• Apply to clean, dry, non‑hairy skin and avoid heat sources that can increase drug absorption.

Short pharmacist counselling script

• "This is clonidine, prescribed for your blood pressure/ADHD symptoms. Start at the dose shown on the label and we will monitor your blood pressure and heart rate."
• "Expect dry mouth and some drowsiness at first; take at night if that helps. If you use patches we will show you how to apply and rotate them."
• "If you and your GP decide to stop clonidine, we will arrange a slow taper and check your blood pressure regularly."

Monitoring milestones

• Baseline and periodic BP and heart rate checks, especially during titration.
• Renal function if clinically indicated and periodic skin checks for patch users.
• Documentation of counselling in the patient record and signposting to NHS.uk and MHRA Yellow Card reporting for adverse events.

Delivery across the United Kingdom